Collegium Pharmaceutical Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Collegium Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in COLL, but not buy additional shares or sell existing shares.
View analyst ratings for Collegium Pharmaceutical or view top-rated stocks.

Wall Street analysts have given Collegium Pharmaceutical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its earnings results on Thursday, May, 6th. The specialty pharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.30 by $0.11. The specialty pharmaceutical company earned $87.70 million during the quarter, compared to analyst estimates of $81.21 million. Collegium Pharmaceutical had a net margin of 13.06% and a trailing twelve-month return on equity of 24.52%. The company's revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 earnings per share.
View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have increased by 30.8% and is now trading at $22.99.
View which stocks have been most impacted by COVID-19.

Collegium Pharmaceutical issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $330 million-$350 million, compared to the consensus revenue estimate of $339.52 million.

3 brokerages have issued 12-month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $8.00 to $34.00. On average, they expect Collegium Pharmaceutical's stock price to reach $25.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical or view top-rated stocks among Wall Street analysts.

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Some companies that are related to Collegium Pharmaceutical include Nektar Therapeutics (NKTR), Insmed (INSM), PTC Therapeutics (PTCT), IGM Biosciences (IGMS), Cassava Sciences (SAVA), Rocket Pharmaceuticals (RCKT), Dicerna Pharmaceuticals (DRNA), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), Cryoport (CYRX), MorphoSys (MOR), Pacira BioSciences (PCRX), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM) and Corcept Therapeutics (CORT).
View all of COLL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (16.72%), Janus Henderson Group PLC (11.57%), Rubric Capital Management LP (6.87%), Renaissance Technologies LLC (3.59%), Rock Springs Capital Management LP (2.61%) and Great Point Partners LLC (2.44%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Rock Springs Capital Management LP, Renaissance Technologies LLC, Millennium Management LLC, Emerald Advisers LLC, Bank of Montreal Can, AQR Capital Management LLC, and Dimensional Fund Advisors LP. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer, and Shirley R Kuhlmann.
View insider buying and selling activity for Collegium Pharmaceutical or view top insider-selling stocks.

COLL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rubric Capital Management LP, Great Point Partners LLC, Principal Financial Group Inc., Principal Financial Group Inc., Foundry Partners LLC, Bank of New York Mellon Corp, and Point72 Asset Management L.P..
View insider buying and selling activity for Collegium Pharmaceutical or or view top insider-buying stocks.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $22.99.

Collegium Pharmaceutical has a market capitalization of $810.35 million and generates $310.02 million in revenue each year. The specialty pharmaceutical company earns $26.75 million in net income (profit) each year or $0.76 on an earnings per share basis.

Collegium Pharmaceutical employs 234 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.